Table 1.
Baseline characteristics of the patients.
| Romiplostim (n = 151) | Placebo (n = 51) | |
|---|---|---|
| Sex, n (%) | ||
| Female | 101 (66.9) | 37 (72.5) |
| Male | 50 (33.1) | 14 (27.5) |
| Age (y), mean ± SD | 42.1 ± 14.0 | 39.7 ± 13.9 |
| Weight (kg), mean ± SD | 65.7 ± 12.3 | 62.7 ± 10.3 |
| Platelet count (109/L), mean ± SD | 13 ± 7 | 13 ± 7 |
| Platelet count (>10 × 109/L), n (%) | 91 (60.3) | 31 (60.8) |
| Splenectomy, n (%) | 14 (9.3) | 5 (9.8) |
| ECOG performance status, n (%) | ||
| 0 | 71 (47.0) | 31 (60.8) |
| 1 | 80 (53.0) | 19 (37.3) |
| 2 | 0 | 1 (2.0) |
| Concomitant ITP therapy, n (%) | ||
| Yes | 88 (58.3) | 29 (56.9) |
| No | 63 (41.7) | 22 (43.1) |
| ITP treatment history, n (%) | ||
| Corticosteroid | 148 (98.0) | 50 (98.0) |
| intravenous immunoglobulin | 67 (44.4) | 27 (52.9) |
| Vincristine/Vinblastine | 33 (21.9) | 12 (23.5) |
| Danazol | 63 (41.7) | 19 (37.3) |
| Cyclophosphamide | 6 (4.0) | 1 (2.0) |
| Azathioprine | 32 (21.2) | 11 (21.6) |
| Rituximab | 16 (10.6) | 6 (11.8) |
| Helicobacter pylori eradication therapy | 6 (4.0) | 4 (7.8) |
| Other | 127 (84.1) | 47 (92.2) |
ECOG, Eastern Cooperative Oncology Group; ITP, immune thrombocytopenia.